ADC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Archives of Disease in Childhood 1989;64:520-524; doi:10.1136/adc.64.4.520
Copyright © 1989 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tudor-Williams, G
Right arrow Articles by Moxon, E R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tudor-Williams, G
Right arrow Articles by Moxon, E R

Haemophilus influenzae type b conjugate vaccine trial in Oxford: implications for the United Kingdom.

G Tudor-Williams, J Frankland, D Isaacs, R T Mayon-White, J A MacFarlane, D G Rees, E R Moxon

University Department of Paediatrics, Radcliffe Infirmary, Oxford.

The safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine was investigated in 103 infants immunised at 3, 5, and 9 months of age; the infants also received diphtheria, pertussis, and tetanus and polio vaccines. Side effects were compared with 99 matched infants receiving diphtheria, pertussis, and tetanus and polio vaccines only. No serious side effects were observed and the incidence of minor side effects was no greater in the recipients of H influenzae type b conjugate vaccine. Two doses of the vaccine (standard and low) were compared: geometric mean titres of serum anticapsular antibody rose from 0.11 microgram/ml before immunisation to 26.4 micrograms/ml after three immunisations with the standard dose and 14.6 micrograms/ml with the low dose. The geometric mean titre among 21 unimmunized infants at this age was 0.06 micrograms/ml. Both doses therefore generated antibody concentrations likely to be protective after three immunisations. There were no non-responders. Incorporation of an H influenzae type b conjugate vaccine into the primary immunisation schedule has the potential for preventing over 1000 cases of systemic H influenzae type b disease and 50 deaths each year in the United Kingdom.





This article has been cited by other articles:


Home page
JWatch GeneralHome page
EARLY IMMUNIZATION WITH HAEMOPHILUS INFLUENZAE B VACCINE
Journal Watch (General), May 5, 1989; 1989(505): 2 - 2.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1989 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health